WO2006116001A2 - Antibodies for the treatment of cancers - Google Patents
Antibodies for the treatment of cancers Download PDFInfo
- Publication number
- WO2006116001A2 WO2006116001A2 PCT/US2006/014941 US2006014941W WO2006116001A2 WO 2006116001 A2 WO2006116001 A2 WO 2006116001A2 US 2006014941 W US2006014941 W US 2006014941W WO 2006116001 A2 WO2006116001 A2 WO 2006116001A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- egfr
- antibody
- mmc
- cells
- binding molecule
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 55
- 238000011282 treatment Methods 0.000 title description 9
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims abstract description 37
- 229960004857 mitomycin Drugs 0.000 claims abstract description 20
- 108700004675 bleomycetin Proteins 0.000 claims abstract description 18
- QYOAUOAXCQAEMW-UTXKDXHTSA-N bleomycin A5 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCNCCCCN)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QYOAUOAXCQAEMW-UTXKDXHTSA-N 0.000 claims abstract description 18
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 19
- 201000011510 cancer Diseases 0.000 claims description 18
- 229940127089 cytotoxic agent Drugs 0.000 claims description 17
- 231100000433 cytotoxic Toxicity 0.000 claims description 16
- 230000001472 cytotoxic effect Effects 0.000 claims description 16
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 14
- 239000002254 cytotoxic agent Substances 0.000 claims description 11
- 239000002246 antineoplastic agent Substances 0.000 claims description 10
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 229940002612 prodrug Drugs 0.000 claims description 6
- 239000000651 prodrug Substances 0.000 claims description 6
- 230000001093 anti-cancer Effects 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 230000005907 cancer growth Effects 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- 239000002619 cytotoxin Substances 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 230000002147 killing effect Effects 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 11
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 11
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 11
- 230000003115 biocidal effect Effects 0.000 claims 2
- 101710112752 Cytotoxin Proteins 0.000 claims 1
- 230000002022 anti-cellular effect Effects 0.000 abstract description 6
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 3
- 210000000481 breast Anatomy 0.000 abstract description 3
- 208000005017 glioblastoma Diseases 0.000 abstract description 2
- 201000010536 head and neck cancer Diseases 0.000 abstract description 2
- 208000014829 head and neck neoplasm Diseases 0.000 abstract description 2
- 210000003932 urinary bladder Anatomy 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 54
- 102000001301 EGF receptor Human genes 0.000 description 37
- 108060006698 EGF receptor Proteins 0.000 description 37
- 229940127121 immunoconjugate Drugs 0.000 description 22
- 239000000243 solution Substances 0.000 description 13
- -1 radioisotopes Substances 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 230000030833 cell death Effects 0.000 description 8
- 229940082789 erbitux Drugs 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 239000000562 conjugate Substances 0.000 description 7
- 231100000673 dose–response relationship Toxicity 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000021615 conjugation Effects 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229940022353 herceptin Drugs 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 125000005647 linker group Chemical group 0.000 description 6
- 206010041823 squamous cell carcinoma Diseases 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 231100000002 MTT assay Toxicity 0.000 description 5
- 238000000134 MTT assay Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000002784 cytotoxicity assay Methods 0.000 description 5
- 231100000263 cytotoxicity test Toxicity 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000005778 DNA damage Effects 0.000 description 3
- 231100000277 DNA damage Toxicity 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229930192392 Mitomycin Natural products 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 3
- 101710120037 Toxin CcdB Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000022534 cell killing Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000007822 coupling agent Substances 0.000 description 3
- 239000003431 cross linking reagent Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 239000000551 dentifrice Substances 0.000 description 3
- 238000011033 desalting Methods 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GKSPIZSKQWTXQG-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[1-(pyridin-2-yldisulfanyl)ethyl]benzoate Chemical compound C=1C=C(C(=O)ON2C(CCC2=O)=O)C=CC=1C(C)SSC1=CC=CC=N1 GKSPIZSKQWTXQG-UHFFFAOYSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- FBUTXZSKZCQABC-UHFFFAOYSA-N 2-amino-1-methyl-7h-purine-6-thione Chemical compound S=C1N(C)C(N)=NC2=C1NC=N2 FBUTXZSKZCQABC-UHFFFAOYSA-N 0.000 description 2
- VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 238000011729 BALB/c nude mouse Methods 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 108010039491 Ricin Proteins 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 108010001818 alpha-sarcin Proteins 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000000611 antibody drug conjugate Substances 0.000 description 2
- 229940049595 antibody-drug conjugate Drugs 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 239000003972 antineoplastic antibiotic Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 238000012412 chemical coupling Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229940045795 other cytotoxic antibiotic in ATC Drugs 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000036515 potency Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- CQXXYOLFJXSRMT-UHFFFAOYSA-N 5-diazocyclohexa-1,3-diene Chemical class [N-]=[N+]=C1CC=CC=C1 CQXXYOLFJXSRMT-UHFFFAOYSA-N 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 101800002638 Alpha-amanitin Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 108700032819 Croton tiglium crotin II Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710204212 Neocarzinostatin Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- RXGJTYFDKOHJHK-UHFFFAOYSA-N S-deoxo-amaninamide Natural products CCC(C)C1NC(=O)CNC(=O)C2Cc3c(SCC(NC(=O)CNC1=O)C(=O)NC(CC(=O)N)C(=O)N4CC(O)CC4C(=O)NC(C(C)C(O)CO)C(=O)N2)[nH]c5ccccc35 RXGJTYFDKOHJHK-UHFFFAOYSA-N 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 239000004007 alpha amanitin Substances 0.000 description 1
- CIORWBWIBBPXCG-SXZCQOKQSA-N alpha-amanitin Chemical compound O=C1N[C@@H](CC(N)=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@H]1C[S@@](=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-SXZCQOKQSA-N 0.000 description 1
- CIORWBWIBBPXCG-UHFFFAOYSA-N alpha-amanitin Natural products O=C1NC(CC(N)=O)C(=O)N2CC(O)CC2C(=O)NC(C(C)C(O)CO)C(=O)NC(C2)C(=O)NCC(=O)NC(C(C)CC)C(=O)NCC(=O)NC1CS(=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- FIVPIPIDMRVLAY-UHFFFAOYSA-N aspergillin Natural products C1C2=CC=CC(O)C2N2C1(SS1)C(=O)N(C)C1(CO)C2=O FIVPIPIDMRVLAY-UHFFFAOYSA-N 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
- 229930195731 calicheamicin Natural products 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 229960005052 demecolcine Drugs 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 108010028531 enomycin Proteins 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- FIVPIPIDMRVLAY-RBJBARPLSA-N gliotoxin Chemical compound C1C2=CC=C[C@H](O)[C@H]2N2[C@]1(SS1)C(=O)N(C)[C@@]1(CO)C2=O FIVPIPIDMRVLAY-RBJBARPLSA-N 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000009629 growth pathway Effects 0.000 description 1
- 201000003911 head and neck carcinoma Diseases 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000002687 intercalation Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 108010010621 modeccin Proteins 0.000 description 1
- 229940125645 monoclonal antibody drug Drugs 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 108010076042 phenomycin Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- PXSOHRWMIRDKMP-UHFFFAOYSA-N triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- 229960005502 α-amanitin Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Definitions
- the present invention relates to anti-EGFR immunoconjugates and methods of using the same for treating cancers.
- EGFR Epidermal growth factor receptor
- Activation of the EGFR autocrine growth pathway in cancer cells can be attributable to several mechanisms, namely, EGFR overexpression, increased concentration of ligand(s), decreased phosphatase activity, decreased receptor turnover, and the presence of aberrant receptors.
- Administration of blocking anti-EGFR antibodies only is not so therapeutic to those cancers independent to ligand binding.
- Currently-used anticancer drugs are unable to recognize tumor cells from normal cells. The amount of an anticancer drug required to achieve a clinically effective level of cell kill often causes severe damage to actively propagating nonmalignant cells such as cells of the gastrointestinal tract and bone marrow, resulting in a variety of undesirable side effects.
- the present invention features additional anti-EGFR immunoconjugates and methods of using the same for suppressing the growth of tumor cells and for treating cancers of epithelial origin.
- the present invention features EGFR-binding molecules.
- Each molecule comprises an antigen-binding fragment of an anti-EGFR monoclonal antibody and a cytotoxic agent.
- an EGFR-binding molecule of the present invention is a monoclonal antibody LAl or LA22 conjugated with a cytotoxic agent.
- cytotoxic agent can be conjugated with the EGFR-binding molecules.
- Non-limiting examples of cytotoxic agents include cytotoxic antibiotics, chemotherapeutic agents, radioisotopes, cytotoxins, or anti-cancer pro-drug activating enzymes.
- the cytotoxic agent being conjugated is mitomycin C or pingyangmycin.
- the present invention also features humanized or engineered antibodies comprising an antigen-binding fragment of LAl or LA22 conjugated with mitomycin C, pingyangmycin, or other anti-cellular agents.
- the present invention features other anti-EGFR antibodies conjugated with mitomycin C or pingyangmycin. These antibodies can be monoclonal antibodies, human antibodies, humanized or engineered antibodies, synthetic antibodies, or single chain antibodies.
- the EGFR-binding molecules or antibodies of the present invention can be used to kill or inhibit the growth of cancer cells. These methods comprise contacting cancer cells with an EGFR-binding molecule or antibody of the present invention.
- the EGFR-binding molecules or antibodies of the present invention can be used to treat cancers. These methods comprise administrating an effective amount of an EGFR-binding molecule or antibody of the present invention to a subject in need thereof. Cancers or cancer cells amenable to the present invention include those of epithelial origin.
- the present invention also features pharmaceutical compositions comprising an EGFR-binding molecule or antibody of the present invention.
- FIGURE 1 demonstrates the cytotoxic effects of anti-EGFR monoclonal antibodies conjugated with pingyangmycin or mitomycin C on human epidermoid carcinoma cells.
- FIGURE 2 illustrates the dose-dependent cytotoxic effect of monoclonal antibody LA22 conjugated with pingyangmycin or mitomycin C on human epidermoid carcinoma cells.
- FIGURE 3A and 3B show the in vitro cytotoxic effect of LA22-MMC immunoconjugate, MMC and naked mAb LA22 on A431 and A549 cells.
- FIGURE 4 shows the dose-dependent cytotoxic effect of monoclonal antibody
- FIGURE 5 demonstrates the dose-dependent cytotoxic effect of monoclonal antibody LAl conjugated with pingyangmycin or mitomycin C on human lung cells.
- FIGURE 6 illustrates the in vivo tumor toxicity effect of LA22-MMC on female Balb/c mice.
- FIGURE 6A shows the treatment scheme of LA22-MMC immunoconjugate on A431 xenografts and the inhibitory effect of tumor growth in vivo.
- FIGURE 6B summarizes the tumor size and percent of tumor inhibition of each of the treatment groups (control, MMC, and LA22-MMC at 0.0032 mg/kg and 0.08 mg/kg).
- FIGURE 7 shows the biodistribution of LA22-MMC immunoconjugate on tumor-bearing mice after 125 I-radiolabeling and immunoscintigraphy.
- FIGURE 8 compares the in vitro cytotoxic effect of LA22-MMC immunoconjugate on human epidermoid carcinoma cells with Erbitux -MMC and
- Herceptin ® -MMC Herceptin ® -MMC.
- the present invention features anti-EGFR monoclonal antibodies LAl or
- LA22 conjugated with cytotoxic or anticellular agents Both LAl and LA22 are commercially available from Upstate USA, Inc., Charlottesville, VA. Monoclonal antibody LA22 is also described in U.S. Patent No. 5,459,061, which is incorporated herein by reference in its entirety.
- Non-limiting examples of suitable cytotoxic or anti-cellular agents include chemotherapeutic agents, radioisotopes, and cytotoxins.
- Specific examples of cytotoxic or anti-cellular agents include, but are not limited to, cytotoxic antibiotics (such as mitomycin C or pingyangmycin), hormones (such as steroids), anti-metabolites (such as cytosine arabinoside, fluorouracil, methotrexate or aminopterin), anthracycline, vinca alkaloids, demecolcine, etoposide, mithramycin, alkylating agents (such as chlorambucil or melphalan), doxorubicin, daunomycin, methotrexate, vinblastine, neocarzinostatin, macromycin, trenimon, ⁇ -amanitin, ricin, ricin A-chain, daunorubicin, taxol, ethiduim bromide, mitomycin, etoposide, ten
- LAl or LA22 monoclonal antibodies can also be conjugated to an anti-cancer pro-drug activating enzyme capable of converting a pro-drug to its active form. See, for example, U.S. Patent No. 4,975,287, which is incorporated herein by reference in its entirety.
- Linking or coupling one or more cytotoxic moieties to an antibody can be achieved by a variety of mechanisms, for example, covalent binding, affinity binding, intercalation, coordinate binding and complexation.
- Preferred binding methods are those involving covalent binding, such as using chemical cross-linkers, natural peptides or disulfide bonds.
- the covalent binding can be achieved either by direct condensation of existing side chains or by the incorporation of external bridging molecules.
- Many bivalent or polyvalent agents are useful in coupling protein molecules to other proteins, peptides or amine functions.
- Examples of coupling agents are carbodiimides, diisocyanates, glutaraldehyde, diazobenzenes, and hexamethylene diamines. This list is not intended to be exhaustive of the various coupling agents known in the art but, rather, is exemplary of the more common coupling agents that may be used.
- an antibody is first derivatized, following by attachment of the cytotoxic component to the derivatized product.
- the term "derivatize” refers to the chemical modification of the antibody substrate with a suitable cross-linking agent.
- cross-linking agents include the disulfide-bond containing linkers SPDP (N-succinimidyl-3-(2-pyr ⁇ dyldithio)propionate) and SMPT (4-succinimidyl-oxycarbonyl- ⁇ -methyl- ⁇ (2-pyridyldithio)toluene).
- Biologically-releasable bonds can also be employed in constructing a clinically-active immunoconjugate, such that the cytotoxic moiety is capable of being released from the antibody once it has entered the target cell.
- Numerous types of linking constructs are known, including simply direct disulfide bond formation between sulfhydryl groups contained on amino acids such as cysteine, or otherwise introduced into respective protein structures, and disulfide linkages using available or designed linker moieties.
- Numerous types of disulfide-bond containing linkers are known, which can successfully be employed to conjugate cytotoxic moieties to antibodies.
- linkers are preferred, such as, for example, sterically hindered disulfide bond linkers, due to their greater stability in vivo, thus preventing release of the toxin moiety prior to binding at the site of action.
- Another preferred cross-linking reagent is SMPT, although other linkers such as SATA, SPDP and 2-iminothiolane may also be employed.
- the conjugate can be purified to remove contaminants such as unconjugated cytotoxic agents or antibodies. In many cases, it is important to remove unconjugated cytotoxic agents because of the possibility of increased toxicity. Moreover, unconjugated antibodies may be removed to avoid the possibility of competition for the antigen between conjugated and unconjugated species. Numerous purification techniques can be used to provide conjugates to a sufficient degree of purity to render them clinically useful.
- the present invention also features anti-EGFR molecules comprising the antigen-binding fragments of LA22 or LAl monoclonal antibodies conjugated with cytotoxic or anticellular agents. These antigen-binding fragments can include or consist of the scFv, diabody, minibody, Fab, F(ab') 2 , or Fv fragments of LA22 or LAl 1 monoclonal antibodies.
- the anti-EGFR molecules of the present invention are humanized or engineered monoclonal antibodies prepared from monoclonal antibodies LA22 or LAl. Humanized or engineered antibodies are particularly desirable for therapeutic treatment of human subjects.
- Humanized or engineered forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, or antigen-binding fragments thereof (such as scFv, diabody, minibody, Fab, or F(ab') 2 ), which contain minimal sequence derived from non-human immunoglobulin.
- Humanized or engineered antibodies are derived from human immunoglobulins in which the residues forming the complementary determining regions (CDRs) are replaced by the residues from CDRs of a non-human antibody, such as LA22 or LAl.
- CDRs complementary determining regions
- Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues.
- Humanized or engineered antibodies may also comprise residues, which are found neither in the recipient antibody nor in the imported CDR or framework sequences.
- the humanized or engineered antibody can comprise at least one or two variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the constant regions are those of a human immunoglobulin consensus sequence.
- humanized or engineered antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection.”
- a selected non-human monoclonal antibody e.g., a murine antibody
- the methods, as described in U.S. Patent Nos. 6,639,055 and 6,794,132, both of which are incorporated herein by reference, can also be used to prepare humanized or engineered antibodies.
- the present invention features other anti-EGFR antibodies conjugated with mitomycin C, pingyangmycin, or other cytotoxic antibiotics.
- Antibodies suitable for this purpose include, but are not limited to, polyclonal, monoclonal, monospecific, poly-specific, non-specific, humanized or engineered, human, single-chain, chimeric, synthetic, recombinant, hybrid, mutated, grafted, or in vitro generated antibodies.
- an antibody of the present invention binds to an epitope in the extracellular domain of EGFR and has an EGFR-binding affinity of at least 10 "5 M “1 , 10 "6 M “1 , 10 "7 M “1 , 10 “ 8 M “1 , 10 “9 M “1 , 10 '10 M '1 , or stronger.
- the scFv, diabody, minibody, Fab, F(ab') 2 , or Fv fragments of these antibodies can also be used for the conjugation of mitomycin C, pingyangmycin, or other cytotoxic antibiotics.
- a pharmaceutical composition of the present invention typically includes an EGFR-binding molecule of the present invention (e.g., mitomycin C- or pingyangmycin-conjugated LA22 or LAl) and a pharmacologically-acceptable carrier.
- EGFR-binding molecule of the present invention e.g., mitomycin C- or pingyangmycin-conjugated LA22 or LAl
- pharmacologically-acceptable carrier includes any and all solvents, dispersion media, coatings, anti-bacterial and anti-fungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically-active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the vectors or cells of the present invention, its use in therapeutic or prophylactic compositions is contemplated. Supplementary active ingredients also can be incorporated into the compositions.
- Administration of a pharmaceutical composition of the present invention can be by way of any common route so long as the target tissue is available via that route. This includes oral, nasal, buccal, rectal, vaginal or topical. Alternatively, administration may be by orthotopic, intradermal, subcutaneous, intramuscular, intraperitoneal, intratumoral, circumferentially, catheterization, or intravenous injection.
- a pharmaceutical composition can also be administered parenterally or intraperitoneally.
- Solutions of the active compounds as free base or pharmacologically- acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose.
- Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.
- the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
- the form is sterile and fluid to the extent that easy syringability exists. It is preferably also stable under the conditions of manufacture and storage and preserved against the contaminating action of microorganisms, such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, or vegetable oils.
- the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion, or by the use of surfactants.
- the prevention of the action of microorganisms can be brought about by various anti-bacterial or anti-fungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal or the like.
- isotonic agents for example, sugars or sodium chloride.
- Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions can be prepared by incorporating an EGFR-binding molecule of the present invention in the required amount in an appropriate solvent with various other ingredients enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle, which contains the basic dispersion medium and the required other ingredients from those enumerated above.
- the preferred methods of preparation are vacuum-drying or freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- an EGFR-binding molecule of the present invention can be incorporated with excipients and used in the form of non-ingestible mouthwashes and dentifrices.
- a mouthwash may be prepared incorporating the active ingredient in the required amount in an appropriate solvent, such as a sodium borate solution (Dobell's Solution).
- an EGFR-binding molecule may be incorporated into an anti-septic wash containing sodium borate, glycerin and potassium bicarbonate.
- An EGFR-binding molecule may also be dispersed in dentifrices, including: gels, pastes, powders, or slurries.
- An EGFR- binding molecule may be added in a therapeutically or prophylactically effective amount to a paste dentifrice that may include water, binders, abrasives, flavoring agents, foaming agents, or humectants.
- compositions of the present invention may be formulated in a neutral or salt form.
- Pharmaceutically-acceptable salts include the acid addition salts formed with the free amino groups of the protein or formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.
- compositions or solutions Upon formulation, compositions or solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically or prophylactically effective.
- the formulations are easily administered in a variety of dosage forms such as injectable solutions, drug release capsules and the like.
- parenteral administration in an aqueous solution for example, the solution can be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
- aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous, and intraperitoneal administration.
- sterile aqueous media which can be employed will be known to those of skill in the art in light of the present disclosure.
- one dosage could be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion, (see, for example, REMINGTON'S PHARMACEUTICAL SCIENCES (15th Edition), pages 1035- 1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated.
- the EGFR-binding molecules of the present invention can be used to kill or inhibit the growth of cancer cells.
- the EGFR-binding molecules of the present invention can also be used to treat cancers in patients or animals.
- cancers that are amenable to the present invention include, but are not limited to, cancers of epithelial origin, such as glioblastoma, cancer of the lung, breast, head and neck, and bladder, or other epidermoid cancers.
- the EGFR-binding molecule of the present invention.
- the EGFR-binding molecule would be provided in an amount effective to kill or inhibit proliferation of the tumor cells.
- the EGFR-binding molecules can also be combined with other traditional therapies to treat cancers.
- Agents or factors suitable for use in a combined therapy are any chemical compound or treatment method that induces DNA damage when applied to a cell. Such agents and factors include radiation and waves that induce DNA damage such as, ⁇ - irradiation, X-rays, UV-irradiation, microwaves, electronic emissions, and the like.
- Chemotherapeutic agents contemplated to be of use include, e.g., adriamycin, 5- fluorouracil (5FU), etoposide (VP- 16), camptothecin, actinomycin-D, mitomycin C, cisplatin (CDDP), and in some cases, hydrogen peroxide.
- LA22 hybridoma (ATCC No. HB 10342) cells at 2x10 4 cell density were injected to Balb/c nude mice. Monoclonal antibodies from ascites was purified using Protein G affinity agarose beads (Upstate, Lake Placid, NY). Briefly, ascites fluid was diluted 1 : 1 with PBS (pH 7.4) and centrifuged at 14,00Og for 4 min. Supernatant was carefully collected and loaded onto a Protein G column (containing 2 mL Protein G agarose) and a 10 mL PBS was then applied to the column to wash unbound components.
- Bound mAb LA22 was eluted with elution buffer (50 mM glycine-HCl, pH 2.7) and transferred into PBS (pH 7.4) by Desalting Column (Pierce, Rockford, IL). Aliquots were analyzed for purity with SDS- PAGE. Concentration of mAb LA22 was determined to be at 1 mg/ml of mouse IgG, which was equivalent to an O.D. (optical density) reading of 1.40. [0050] The A431 human epidermoid carcinoma cells, which express large quantities of EGFR, and A549 human lung adenocarcinoma cells were used for in vitro cytotoxicity assays.
- DMEM Dulbecco's Modified Eagle medium
- FBS fetal bovine serum
- MMC Kyowa Hakko Kogyo, Tokyo, Japan
- PYM pingyangmycin
- SPDP iV-Succinimidyl 3- (2-pyridyldithio) propionate
- Fig. 1 See Knoll, K. et ah, Cancer Res., 60:6089-6094, 2000.
- MMC (10 mg in 5 mL PBS) was reacted with 0.9 mL of SPDP (Pierce, Rockford, IL) stock (10 mg in 1 mL DMF) at 4°C for 6 h. The resulting solution was stored in small aliquots at -80°C until further use.
- mAb LA22 5.5 mg in 3 mL of PBS
- mAb LAl was reduced by adding 46 ⁇ L of 2-iminothiolane (4.4 mg dissolved in 1 mL DMF) for 1 h under nitrogen. The reduced antibody was purified by size exclusion chromatography using a desalting column (Pierce, Rockford, IL), that was pre-equilibrated with PBS.
- LA22-MMC or LA22-PMC
- A431 cells a human epidermoid carcinoma cell line (ATCC No. CRL-1551), were seeded at 2,000 cells/well of 96-well plate in DMEM-10% FBS.
- mAb LA22 40 nM
- LA22-PYM immunoco ⁇ jugate LA22-P, 40 nM
- LA22-MMC immunoco ⁇ jugate LA22-M, 40 nM
- mAb LAl 40 nM
- LAl-PYM immunoconjugate LAl-P, 40 nM
- LAl-MMC immunoconjugate LAl-M, 40 nM
- PYM- SPDP P-Linker, 40 nM
- MMC-SPDP M-Linker, 40 nM
- FIGURE 2 illustrates that anti-EGFR mAb LA22-PYM or LA22- MMC induced the death of A431 human cancer cells in a dose-dependent manner.
- Another LA22-MMC cytotoxicity assay was performed with additional controls.
- the A431 cells, as well as human lung adenocarcinoma A549 cells were plated (2x10 3 cells/well, 100 ⁇ L/well) in 96-well cell culture plates (Corning, Corning, NY) in the presence of DMEM medium and 10% FBS for 4 h at 37 °C, 5% CO 2 .
- MMC, naked mAb LA22 or LA22-MMC immunoconjugate in serum-free DMEM medium (100 ⁇ L) were added onto the individual wells and incubated for 4 days at 37°C and 5% CO 2 . The supernatants were discarded first. For dead cells control, 100 ⁇ L of cold 95% ethanol was added into the well for 1 min then discarded.
- MTT solutions (USB, Cleveland, OH; 10% in DMEM medium) were added (100 ⁇ L/well) and incubated for 4 h at 37°C. The supernatants were discarded and DMSO was added (100 ⁇ L/well) to dissolve the precipitates. Optical density was read at 570 nm using a microplate reader (Bio-Rad, Hercules, CA). [0056] , The above-mentioned inhibition of A431/A549 in vitro cell growth was used as a measure for drug activity in vitro and was determined by exposing cultured cells (2x10 3 cells/well) for 4 days at 37°C with MMC, LA22-MMC or LA22.
- the tested MMC concentrations ranged from 0.03 ⁇ g/mL to 30 ⁇ g/mL.
- the dosage of the LA22-MMC conjugate for cytotoxicity was calculated according to the total amount of MMC added in chemical coupling reaction. Because the efficiency of chemical coupling reactions was not 100%, theoretically the real MMC concentration linked to LA22 was lower than indicated concentration. The dosage of LA22 was the same as LA22-MMC.
- Non-specific mouse IgG (as a negative control) was labeled with MMC and added into A431 cells to evaluate its cytotoxicity on cell growth in vitro. The result showed that non-specific mouse IgG-MMC immunoconjugates did not kill cultured cells as efficiently as LA22-MMC, which proved that the cytotoxicity of LA22-MMC can be mediated via LA22-EGFR binding (data not included).
- an in vitro cytotoxicity assay employing LAl -antibiotic immunoconjugates was similarly evaluated.
- A431 cells were seeded at 2,000 cells/well of 96-well plate in DMEM-10% FBS. 4 hr later, various amounts of LAl, LAl-PYM, or LAl- MMC were added to the cell cultures. Four days late, the cell numbers in each well were determined by MTT assay. The numbers were expressed as the percentage of the cell death (FIGURE 4).
- mAb LAl and its immunoconjugates induced the death of A431 human cancer cells in a dose-dependent manner. Conjugation with either pingyangmycin or mitomycin C significantly increased the cell killing potencies of mAb LAl.
- A549 cell line (ATCC No. CCL-185).
- A549 cells were seeded at 2,000 cells/well of 96-well plate in DMEM-10% FBS.
- various amounts of LAl, LAl-MMC, or MMC-SPDP were added to the cell cultures.
- the cell numbers in each well were determined by MTT assay. The numbers were expressed as the percentage of the cell death (FIGURE 5).
- LAl-MMC induced the death of A549 human lung cancer cells in a dose-dependent manner. No significant cell death was observed with mAb LAl alone. Conjugation with mitomycin C significantly increased the cell killing potency of LAl.
- mice were used to test for the effect of LA22-MMC on in vivo tumor toxicity.
- Xenografts of A431 cell lines were produced by injecting 2x10 6 tumor cells (resuspended in 0.2 rnL PBS) subcutaneously into the right front leg of mice on day 0.
- the mice were grouped (5 mice per group) and administered intraperitoneally with PBS, MMC, naked antibodies or immunoconjugates with indicated concentrations on day 1, day 5 and day 9.
- mice treated with LA22-MMC (0.08 mg/kg) inhibited tumor growth in vivo when compared with control untreated mice.
- MMC (0.08 mg/kg) injection was potent to inhibit tumor growth, the efficiency was much lower than LA22-MMC (0.08 mg/kg), which suggested the great advantage of LA22-mediated specific tumor targeting.
- Low dosage administration (0.0032 mg/kg) of LA22-MMC was not potent as the high-dosage of LA22-MMC administration (0.08 mg/kg), which suggested the dose-dependent effect of LA22-MMC immunoconjugate.
- mice were sacrificed and the tumors were weighed (FIGURE 6B).
- the nude mice- bearing A431/A549 xenografts were injected intravenously with 17.6 MBq ( ⁇ 20 ⁇ g, 0.3 mL) of 125 I-LA22-MMC, and placed prone on a two-head ⁇ -camera (E.CAM, Siemens, Kunststoff, Germany) equipped with a parallel-hole, low-energy, high-resolution collimator.
- the posterior images were acquired at different time points post-injection for the visual observation of in vivo distribution of LA22-MMC, and stored digitally in a 128 x 128 matrix.
- the acquisition count limits were set at 1000 K.
- LA22-MMC first distributed in the circulation system and blood-rich tissues such as liver or heart (4h imaging); gradually the labeled immunoconjugates enriched on the tumor sites (1 day to 4 days). After 4 days, LA22-MMC mainly enriched on the tumor sites.
- Erbitux ® and Herceptin ® two commercially-available mAb drugs for cancer therapy, target EGFR and HER2, respectively. Both EGFR and HER2 belong to the ErbB receptor family (Mendelsohn, J. et ah, Oncogene, 19:6550-7565, 2000).
- Erbitux ® and Herceptin ® an in vitro cytotoxicity assay using the MTT method was conducted. The conjugation of MMC with Erbitux ® (ImClone, New York, NY) or Herceptin ® (Genentech, San Francisco, CA) or mouse IgG was done as described above.
- Erbitux ® and Herceptin ® were labeled with MMC and evaluated for their cytotoxicities.
- A431 (FIGURE 8A) or A549 (FIGURE 8B) cells were seeded into 96-well cell culture plates. Naked antibodies or immunoconjugates were added to wells and incubated for 4 days at 37°C and 5% CO 2 . Viable cells were measured using the MTT assay. Using similar antibody concentrations, LA22-MMC prodrug killed A431 and A549 cells more efficiently than Erbitux ® -MMC or Herceptin ® -MMC (see FIGURES 8A & 8B) .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present invention features monoclonal antibodies LA1 or LA22 conjugated with mitomycin C, pingyangmycin or other anti-cellular agents. The present invention also features other anti-EGFR antibodies conjugated with mitomycin C or pingyangmycin. The antibodies of the present invention can be used to treat cancers, including but not limited to, those of epithelial origin, such as glioblastoma or cancer of the lung, breast, head and neck, and bladder.
Description
ANTIBODIES FOR THE TREATMENT OF CANCERS
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] The present application claims priority from and incorporates by reference the entire disclosure of U.S. Provisional Patent Application Serial No. 60/675,094, filed April 27,
2005.
TECHNICAL FIELD
[0002] The present invention relates to anti-EGFR immunoconjugates and methods of using the same for treating cancers.
BACKGROUND
[0003] Epidermal growth factor receptor (EGFR) is a transmembrane protein involved in signaling pathways essential for cell proliferation. Over-expression of this receptor often accompanies development and growth of malignant tumors. There is increasing evidence that high expression of EGFR is correlated with aggressive tumor growth, as well as with poor clinical outcome of common cancers in humans, including breast, cervix, lung, and head and neck carcinomas (Baselga, J. et ah, J. Clin. Oncol., 18:904- 914, 2000; Nicholson, R. I. et ah, Eur. J. Cancer, 37:S9-S15, 2001). The critical role the EGFR plays in cancer has led to an extensive search for selective inhibitors of the EGFR signaling pathway. Development of monoclonal antibodies to prevent ligand binding to the EGFR is one promising strategy, which was first proposed by J. Mendelsohn in the 1980s (Ciardello, F. et at., Clin. Cancer Res., 7:2958-2970, 2001. Erbitux® was the first approved anti-EGFR monoclonal antibody drug with anticancer activity in the market. Besides Erbitux , at least three other blocking monoclonal antibodies have been developed against the EGFR (Speake, G. et al., Curr. Opin. Pharmacol, 5:343-349, 2005). [0004] Activation of the EGFR autocrine growth pathway in cancer cells can be attributable to several mechanisms, namely, EGFR overexpression, increased concentration of ligand(s), decreased phosphatase activity, decreased receptor turnover, and the presence of aberrant receptors. Administration of blocking anti-EGFR antibodies only is not so therapeutic to those cancers independent to ligand binding. Currently-used anticancer drugs are unable to recognize tumor cells from normal cells. The amount of an anticancer drug required to achieve a clinically effective level of cell kill often causes severe damage to
actively propagating nonmalignant cells such as cells of the gastrointestinal tract and bone marrow, resulting in a variety of undesirable side effects. This property dictates a careful balance in treatment schedules between killing the tumor cells and excessive toxicity to the patient, which creates the major obstacle in cancer chemotherapy. Such considerations often impose administration of doses that are limited in efficiency (Aboud-Pirak, E. et ah, Proc. Natl. Acad. ScL USA, 86:3778-3781, 1989). Targeted biological therapies that selectively interfere with cancer cells may improve the therapeutic efficacy without increasing treatment- related toxicity. EGFR-mediated specific tumor delivery of anticancer agents by anti-EGFR antibody-drug conjugate is an alternative strategy whose therapeutic effects are independent to ligand binding to EGFR (Aboud-Pirak, E. et al. supra; Mamot, C. et al., Cancer Res. 63:3154-3161, 2003). Theoretically, conjugation of a drug to an antibody renders the drug inactive. Once at the tumor site, the conjugate binds to the surface of tumor cells and is further internalized to release the drug to kill tumor cells. Such antibody-drug conjugates are also considered as tumor-activated pro-drugs (Lambert, J. M., Curr. Opin. Phamacol., 5:543- 549, 2005). Based on the above, it is, therefore, very important to develop new chemotherapeutic agents with improved tumor specificity and favorable anti-cancer activities.
SUMMARY OF THE INVENTION
[0005] The present invention features additional anti-EGFR immunoconjugates and methods of using the same for suppressing the growth of tumor cells and for treating cancers of epithelial origin. In one aspect, the present invention features EGFR-binding molecules.
Each molecule comprises an antigen-binding fragment of an anti-EGFR monoclonal antibody and a cytotoxic agent. In one embodiment, an EGFR-binding molecule of the present invention is a monoclonal antibody LAl or LA22 conjugated with a cytotoxic agent.
[0006] Any type of cytotoxic agent can be conjugated with the EGFR-binding molecules. Non-limiting examples of cytotoxic agents include cytotoxic antibiotics, chemotherapeutic agents, radioisotopes, cytotoxins, or anti-cancer pro-drug activating enzymes. In one example, the cytotoxic agent being conjugated is mitomycin C or pingyangmycin.
[0007] The present invention also features humanized or engineered antibodies comprising an antigen-binding fragment of LAl or LA22 conjugated with mitomycin C, pingyangmycin, or other anti-cellular agents.
[0008] In addition, the present invention features other anti-EGFR antibodies conjugated with mitomycin C or pingyangmycin. These antibodies can be monoclonal antibodies, human antibodies, humanized or engineered antibodies, synthetic antibodies, or single chain antibodies.
[0009] The EGFR-binding molecules or antibodies of the present invention can be used to kill or inhibit the growth of cancer cells. These methods comprise contacting cancer cells with an EGFR-binding molecule or antibody of the present invention.
[0010] In addition, the EGFR-binding molecules or antibodies of the present invention can be used to treat cancers. These methods comprise administrating an effective amount of an EGFR-binding molecule or antibody of the present invention to a subject in need thereof. Cancers or cancer cells amenable to the present invention include those of epithelial origin.
[0011] Furthermore, the present invention also features pharmaceutical compositions comprising an EGFR-binding molecule or antibody of the present invention.
[0012] Other features, objects, and advantages of the present invention are apparent in the detailed description that follows. It should be understood, however, that the detailed description, while indicating embodiments of the present invention, is given by way of illustration only, not limitation. Various changes and modifications within the scope of the invention will become apparent to those skilled in the art from the detailed description.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013] The drawings are provided for illustration, not limitation.
[0014] FIGURE 1 demonstrates the cytotoxic effects of anti-EGFR monoclonal antibodies conjugated with pingyangmycin or mitomycin C on human epidermoid carcinoma cells.
[0015] FIGURE 2 illustrates the dose-dependent cytotoxic effect of monoclonal antibody LA22 conjugated with pingyangmycin or mitomycin C on human epidermoid carcinoma cells.
[0016] FIGURE 3A and 3B show the in vitro cytotoxic effect of LA22-MMC immunoconjugate, MMC and naked mAb LA22 on A431 and A549 cells.
[0017] FIGURE 4 shows the dose-dependent cytotoxic effect of monoclonal antibody
LAl conjugated with pingyangmycin or mitomycin C on human epidermoid carcinoma cells.
[0018] FIGURE 5 demonstrates the dose-dependent cytotoxic effect of monoclonal antibody LAl conjugated with pingyangmycin or mitomycin C on human lung cells.
[0019] FIGURE 6 illustrates the in vivo tumor toxicity effect of LA22-MMC on female Balb/c mice. FIGURE 6A shows the treatment scheme of LA22-MMC immunoconjugate on A431 xenografts and the inhibitory effect of tumor growth in vivo.
FIGURE 6B summarizes the tumor size and percent of tumor inhibition of each of the treatment groups (control, MMC, and LA22-MMC at 0.0032 mg/kg and 0.08 mg/kg).
[0020] FIGURE 7 shows the biodistribution of LA22-MMC immunoconjugate on tumor-bearing mice after 125I-radiolabeling and immunoscintigraphy.
[0021] FIGURE 8 compares the in vitro cytotoxic effect of LA22-MMC immunoconjugate on human epidermoid carcinoma cells with Erbitux -MMC and
Herceptin®-MMC.
DETAILED DESCRIPTION
[0022] The present invention features anti-EGFR monoclonal antibodies LAl or
LA22 conjugated with cytotoxic or anticellular agents. Both LAl and LA22 are commercially available from Upstate USA, Inc., Charlottesville, VA. Monoclonal antibody LA22 is also described in U.S. Patent No. 5,459,061, which is incorporated herein by reference in its entirety.
[0023] Non-limiting examples of suitable cytotoxic or anti-cellular agents include chemotherapeutic agents, radioisotopes, and cytotoxins. Specific examples of cytotoxic or anti-cellular agents include, but are not limited to, cytotoxic antibiotics (such as mitomycin C or pingyangmycin), hormones (such as steroids), anti-metabolites (such as cytosine arabinoside, fluorouracil, methotrexate or aminopterin), anthracycline, vinca alkaloids, demecolcine, etoposide, mithramycin, alkylating agents (such as chlorambucil or melphalan), doxorubicin, daunomycin, methotrexate, vinblastine, neocarzinostatin, macromycin, trenimon, α-amanitin, ricin, ricin A-chain, daunorubicin, taxol, ethiduim bromide, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, actinomycin D, diphteria toxin, Pseudomonas exotoxin (PE) A, PE40, abrin, arbrin A chain, modeccin A chain, alpha-sarcin, gelonin, mitogellin, retstrictocin, phenomycin, enomycin, α- sarcin, aspergillin, restirictocin, a ribonuclease, diphtheria toxin, pseudomonas exotoxin, curicin, crotin, calicheamicin, sapaonaria officinalis inhibitor, maytansinoids, glucocorticoid, and radioisotopes.
[0024] LAl or LA22 monoclonal antibodies can also be conjugated to an anti-cancer pro-drug activating enzyme capable of converting a pro-drug to its active form. See, for example, U.S. Patent No. 4,975,287, which is incorporated herein by reference in its entirety. [0025] Linking or coupling one or more cytotoxic moieties to an antibody can be achieved by a variety of mechanisms, for example, covalent binding, affinity binding, intercalation, coordinate binding and complexation. Preferred binding methods are those involving covalent binding, such as using chemical cross-linkers, natural peptides or disulfide bonds.
[0026] The covalent binding can be achieved either by direct condensation of existing side chains or by the incorporation of external bridging molecules. Many bivalent or polyvalent agents are useful in coupling protein molecules to other proteins, peptides or amine functions. Examples of coupling agents are carbodiimides, diisocyanates, glutaraldehyde, diazobenzenes, and hexamethylene diamines. This list is not intended to be exhaustive of the various coupling agents known in the art but, rather, is exemplary of the more common coupling agents that may be used.
[0027] In many embodiments, an antibody is first derivatized, following by attachment of the cytotoxic component to the derivatized product. As used herein, the term "derivatize" refers to the chemical modification of the antibody substrate with a suitable cross-linking agent. Examples of cross-linking agents for use in this manner include the disulfide-bond containing linkers SPDP (N-succinimidyl-3-(2-pyrϊdyldithio)propionate) and SMPT (4-succinimidyl-oxycarbonyl-α-methyl-α(2-pyridyldithio)toluene). [0028] Biologically-releasable bonds can also be employed in constructing a clinically-active immunoconjugate, such that the cytotoxic moiety is capable of being released from the antibody once it has entered the target cell. Numerous types of linking constructs are known, including simply direct disulfide bond formation between sulfhydryl groups contained on amino acids such as cysteine, or otherwise introduced into respective protein structures, and disulfide linkages using available or designed linker moieties. [0029] Numerous types of disulfide-bond containing linkers are known, which can successfully be employed to conjugate cytotoxic moieties to antibodies. Certain linkers are preferred, such as, for example, sterically hindered disulfide bond linkers, due to their greater stability in vivo, thus preventing release of the toxin moiety prior to binding at the site of action. Another preferred cross-linking reagent is SMPT, although other linkers such as SATA, SPDP and 2-iminothiolane may also be employed.
[0030] Once conjugated, the conjugate can be purified to remove contaminants such as unconjugated cytotoxic agents or antibodies. In many cases, it is important to remove unconjugated cytotoxic agents because of the possibility of increased toxicity. Moreover, unconjugated antibodies may be removed to avoid the possibility of competition for the antigen between conjugated and unconjugated species. Numerous purification techniques can be used to provide conjugates to a sufficient degree of purity to render them clinically useful.
[0031] The present invention also features anti-EGFR molecules comprising the antigen-binding fragments of LA22 or LAl monoclonal antibodies conjugated with cytotoxic or anticellular agents. These antigen-binding fragments can include or consist of the scFv, diabody, minibody, Fab, F(ab')2, or Fv fragments of LA22 or LAl 1 monoclonal antibodies. [0032] In one embodiment, the anti-EGFR molecules of the present invention are humanized or engineered monoclonal antibodies prepared from monoclonal antibodies LA22 or LAl. Humanized or engineered antibodies are particularly desirable for therapeutic treatment of human subjects. Humanized or engineered forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, or antigen-binding fragments thereof (such as scFv, diabody, minibody, Fab, or F(ab')2), which contain minimal sequence derived from non-human immunoglobulin. Humanized or engineered antibodies are derived from human immunoglobulins in which the residues forming the complementary determining regions (CDRs) are replaced by the residues from CDRs of a non-human antibody, such as LA22 or LAl. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized or engineered antibodies may also comprise residues, which are found neither in the recipient antibody nor in the imported CDR or framework sequences. The humanized or engineered antibody can comprise at least one or two variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the constant regions are those of a human immunoglobulin consensus sequence.
[0033] In addition, humanized or engineered antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody, e.g., a murine antibody, is used to guide the selection of a humanized or engineered antibody recognizing the same epitope.
[0034] The methods, as described in U.S. Patent Nos. 6,639,055 and 6,794,132, both of which are incorporated herein by reference, can also be used to prepare humanized or engineered antibodies.
[0035] Moreover, the present invention features other anti-EGFR antibodies conjugated with mitomycin C, pingyangmycin, or other cytotoxic antibiotics. Antibodies suitable for this purpose include, but are not limited to, polyclonal, monoclonal, monospecific, poly-specific, non-specific, humanized or engineered, human, single-chain, chimeric, synthetic, recombinant, hybrid, mutated, grafted, or in vitro generated antibodies. Preferably, an antibody of the present invention binds to an epitope in the extracellular domain of EGFR and has an EGFR-binding affinity of at least 10"5 M"1, 10"6 M"1, 10"7 M"1, 10" 8 M"1, 10"9 M"1, 10'10 M'1, or stronger. The scFv, diabody, minibody, Fab, F(ab')2, or Fv fragments of these antibodies can also be used for the conjugation of mitomycin C, pingyangmycin, or other cytotoxic antibiotics.
[0036] After a sufficient amount of a purified EGFR-binding molecule has been prepared, one may desire to prepare it into a pharmaceutical composition. A pharmaceutical composition of the present invention typically includes an EGFR-binding molecule of the present invention (e.g., mitomycin C- or pingyangmycin-conjugated LA22 or LAl) and a pharmacologically-acceptable carrier. As used herein, "pharmaceutically-acceptable carrier" includes any and all solvents, dispersion media, coatings, anti-bacterial and anti-fungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically-active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the vectors or cells of the present invention, its use in therapeutic or prophylactic compositions is contemplated. Supplementary active ingredients also can be incorporated into the compositions.
[0037] Administration of a pharmaceutical composition of the present invention can be by way of any common route so long as the target tissue is available via that route. This includes oral, nasal, buccal, rectal, vaginal or topical. Alternatively, administration may be by orthotopic, intradermal, subcutaneous, intramuscular, intraperitoneal, intratumoral, circumferentially, catheterization, or intravenous injection.
[0038] A pharmaceutical composition can also be administered parenterally or intraperitoneally. Solutions of the active compounds as free base or pharmacologically- acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene
glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms. [0039] The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In most cases, the form is sterile and fluid to the extent that easy syringability exists. It is preferably also stable under the conditions of manufacture and storage and preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, or vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion, or by the use of surfactants. The prevention of the action of microorganisms can be brought about by various anti-bacterial or anti-fungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal or the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
[0040] Sterile injectable solutions can be prepared by incorporating an EGFR-binding molecule of the present invention in the required amount in an appropriate solvent with various other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle, which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying or freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
[0041] For oral administration, an EGFR-binding molecule of the present invention can be incorporated with excipients and used in the form of non-ingestible mouthwashes and dentifrices. A mouthwash may be prepared incorporating the active ingredient in the required amount in an appropriate solvent, such as a sodium borate solution (Dobell's Solution). Alternatively, an EGFR-binding molecule may be incorporated into an anti-septic wash containing sodium borate, glycerin and potassium bicarbonate. An EGFR-binding molecule
may also be dispersed in dentifrices, including: gels, pastes, powders, or slurries. An EGFR- binding molecule may be added in a therapeutically or prophylactically effective amount to a paste dentifrice that may include water, binders, abrasives, flavoring agents, foaming agents, or humectants.
[0042] The compositions of the present invention may be formulated in a neutral or salt form. Pharmaceutically-acceptable salts include the acid addition salts formed with the free amino groups of the protein or formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like. [0043] Upon formulation, compositions or solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically or prophylactically effective. The formulations are easily administered in a variety of dosage forms such as injectable solutions, drug release capsules and the like. For parenteral administration in an aqueous solution, for example, the solution can be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous, and intraperitoneal administration. In this connection, sterile aqueous media which can be employed will be known to those of skill in the art in light of the present disclosure. For example, one dosage could be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion, (see, for example, REMINGTON'S PHARMACEUTICAL SCIENCES (15th Edition), pages 1035- 1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated.
[0044] The skilled artisan is directed to REMINGTON'S PHARMACEUTICAL SCIENCES
(15th Edition), Chapter 33, in particular, pages 624-652, the entire contents of which are incorporated herein by reference. Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will determine the appropriate dose for the individual subject.
[0045] The EGFR-binding molecules of the present invention can be used to kill or inhibit the growth of cancer cells. The EGFR-binding molecules of the present invention can also be used to treat cancers in patients or animals. Examples of cancers that are amenable to
the present invention include, but are not limited to, cancers of epithelial origin, such as glioblastoma, cancer of the lung, breast, head and neck, and bladder, or other epidermoid cancers.
[0046] To kill cells or inhibit cell growth, one may contact a target cell with an
EGFR-binding molecule of the present invention. The EGFR-binding molecule would be provided in an amount effective to kill or inhibit proliferation of the tumor cells. [0047] The EGFR-binding molecules can also be combined with other traditional therapies to treat cancers. Agents or factors suitable for use in a combined therapy are any chemical compound or treatment method that induces DNA damage when applied to a cell. Such agents and factors include radiation and waves that induce DNA damage such as, γ- irradiation, X-rays, UV-irradiation, microwaves, electronic emissions, and the like. A variety of chemical compounds, also described as chemotherapeutic agents, function to induce DNA damage, all of which are intended to be of use in the combined treatment methods disclosed herein. Chemotherapeutic agents contemplated to be of use, include, e.g., adriamycin, 5- fluorouracil (5FU), etoposide (VP- 16), camptothecin, actinomycin-D, mitomycin C, cisplatin (CDDP), and in some cases, hydrogen peroxide.
[0048] It should be understood that the above-described embodiments and the following examples are given by way of illustration, not limitation. Various changes and modifications within the scope of the present invention will become apparent to those skilled in the art from the present description.
EXAMPLES Materials and Methods
[0049] LA22 hybridoma (ATCC No. HB 10342) cells at 2x104 cell density were injected to Balb/c nude mice. Monoclonal antibodies from ascites was purified using Protein G affinity agarose beads (Upstate, Lake Placid, NY). Briefly, ascites fluid was diluted 1 : 1 with PBS (pH 7.4) and centrifuged at 14,00Og for 4 min. Supernatant was carefully collected and loaded onto a Protein G column (containing 2 mL Protein G agarose) and a 10 mL PBS was then applied to the column to wash unbound components. Bound mAb LA22 was eluted with elution buffer (50 mM glycine-HCl, pH 2.7) and transferred into PBS (pH 7.4) by Desalting Column (Pierce, Rockford, IL). Aliquots were analyzed for purity with SDS- PAGE. Concentration of mAb LA22 was determined to be at 1 mg/ml of mouse IgG, which was equivalent to an O.D. (optical density) reading of 1.40.
[0050] The A431 human epidermoid carcinoma cells, which express large quantities of EGFR, and A549 human lung adenocarcinoma cells were used for in vitro cytotoxicity assays. These cells were grown at 37 0C in monolayer culture with Dulbecco's Modified Eagle medium (DMEM) containing 10% fetal bovine serum (FBS) (Hyclone, Logan, UT). [0051] The principle used to conjugate small molecule anticancer drug mitomycin
(MMC; Kyowa Hakko Kogyo, Tokyo, Japan) or pingyangmycin (PYM) to anti-EGFR mAb LA22 or LAl involved the activation of the amino group of the mAb with iV-Succinimidyl 3- (2-pyridyldithio) propionate (SPDP), followed by disulfide exchange with iminothiolane- modified mAb LA22 (Fig. 1). See Knoll, K. et ah, Cancer Res., 60:6089-6094, 2000. For activation, MMC (10 mg in 5 mL PBS) was reacted with 0.9 mL of SPDP (Pierce, Rockford, IL) stock (10 mg in 1 mL DMF) at 4°C for 6 h. The resulting solution was stored in small aliquots at -80°C until further use. mAb LA22 (5.5 mg in 3 mL of PBS) or mAb LAl was reduced by adding 46 μL of 2-iminothiolane (4.4 mg dissolved in 1 mL DMF) for 1 h under nitrogen. The reduced antibody was purified by size exclusion chromatography using a desalting column (Pierce, Rockford, IL), that was pre-equilibrated with PBS. The conjugation of activated MMC (Mr: 137) or activated PMC with thiolated mAb LA22 (Mr: ~150 K) or thiolated mAb LAl, respectively, was done at room temperature for 1 h under nitrogen using a 40:1 molar ratio. Excess-free MMC-SPDP or PMC-SPDP was removed using a desalting column (Pierce, Rockford, IL), also pre-equilibrated with PBS. LA22- MMC (or LA22-PMC) or LAl-MMC (or LAl-PMC) products were filter-sterilized using 0.2 μm Supor membrane (Pall, Ann Arbor, MI). The dosage of the LA22-MMC (or LA22-PMC) or LAl-MMC (or LAl-PMC) conjugates for cytotoxicity and/or in vivo experiments was calculated according to the total amount of MMC or PMC added. Aliquots of the final immunoconjugates products were stored at 4 0C prior to use.
Example 1
[0052] A431 cells, a human epidermoid carcinoma cell line (ATCC No. CRL-1551), were seeded at 2,000 cells/well of 96-well plate in DMEM-10% FBS. Four hours later, either control medium, mAb LA22 (40 nM), LA22-PYM immunocoηjugate (LA22-P, 40 nM), LA22-MMC immunocoηjugate (LA22-M, 40 nM), mAb LAl (40 nM), LAl-PYM immunoconjugate (LAl-P, 40 nM), LAl-MMC immunoconjugate (LAl-M, 40 nM), PYM- SPDP (P-Linker, 40 nM), or MMC-SPDP (M-Linker, 40 nM) were added to the cell cultures. Four days later, the cell numbers in each well were determined by MTT assay (Mosmann, J.
Immunol. Methods, 65:55-63 (1983). The numbers were expressed as the percentage of the cell death (FIGURE 1).
[0053] As shown in FIGURE 1, no significant cell death was observed with anti-
EGFR mAb LA22 alone at 40 nM, while LA22-PYM and LA22-MMC led to 42% and 84% cell death, respectively. In the same dosage (40 nM), anti-EGFR mAb LAl alone induced 35% of cell death. Enhanced cell killing activities were observed with LAl-PYM and LAl- MMC immunoconjugates.
Example 2
[0054] To evaluate the concentration dependency of the above-mentioned in vitro cytotoxicity of LA22-antibiotic immunoconjugates, various amounts of LA22, LA22-PYM, and LA22-MMC were added to A431 cell cultures 4 hours after the cells were seeded at 2,000 cells/well of 96-well plate in DMEM-10% FBS. Four days later, the cell numbers in each well were determined by MTT assay. The numbers were expressed as the percentage of the cell death (FIGURE 2). FIGURE 2 illustrates that anti-EGFR mAb LA22-PYM or LA22- MMC induced the death of A431 human cancer cells in a dose-dependent manner. [0055] Another LA22-MMC cytotoxicity assay was performed with additional controls. The A431 cells, as well as human lung adenocarcinoma A549 cells (ATCC No. CCL-185) were plated (2x103 cells/well, 100 μL/well) in 96-well cell culture plates (Corning, Corning, NY) in the presence of DMEM medium and 10% FBS for 4 h at 37 °C, 5% CO2. MMC, naked mAb LA22 or LA22-MMC immunoconjugate in serum-free DMEM medium (100 μL) were added onto the individual wells and incubated for 4 days at 37°C and 5% CO2. The supernatants were discarded first. For dead cells control, 100 μL of cold 95% ethanol was added into the well for 1 min then discarded. MTT solutions (USB, Cleveland, OH; 10% in DMEM medium) were added (100 μL/well) and incubated for 4 h at 37°C. The supernatants were discarded and DMSO was added (100 μL/well) to dissolve the precipitates. Optical density was read at 570 nm using a microplate reader (Bio-Rad, Hercules, CA). [0056] , The above-mentioned inhibition of A431/A549 in vitro cell growth was used as a measure for drug activity in vitro and was determined by exposing cultured cells (2x103 cells/well) for 4 days at 37°C with MMC, LA22-MMC or LA22. The tested MMC concentrations ranged from 0.03 μg/mL to 30 μg/mL. The dosage of the LA22-MMC conjugate for cytotoxicity was calculated according to the total amount of MMC added in chemical coupling reaction. Because the efficiency of chemical coupling reactions was not
100%, theoretically the real MMC concentration linked to LA22 was lower than indicated concentration. The dosage of LA22 was the same as LA22-MMC. These results indicated that MMC conjugated LA22 were less potent than the free MMC alone, but more potent than naked mAb LA22 (see FIGURES 3A and 3B ). Non-specific mouse IgG (as a negative control) was labeled with MMC and added into A431 cells to evaluate its cytotoxicity on cell growth in vitro. The result showed that non-specific mouse IgG-MMC immunoconjugates did not kill cultured cells as efficiently as LA22-MMC, which proved that the cytotoxicity of LA22-MMC can be mediated via LA22-EGFR binding (data not included).
Example 3
[0057] Likewise, an in vitro cytotoxicity assay employing LAl -antibiotic immunoconjugates was similarly evaluated. A431 cells were seeded at 2,000 cells/well of 96-well plate in DMEM-10% FBS. 4 hr later, various amounts of LAl, LAl-PYM, or LAl- MMC were added to the cell cultures. Four days late, the cell numbers in each well were determined by MTT assay. The numbers were expressed as the percentage of the cell death (FIGURE 4). As demonstrated in FIGURE 3, mAb LAl and its immunoconjugates induced the death of A431 human cancer cells in a dose-dependent manner. Conjugation with either pingyangmycin or mitomycin C significantly increased the cell killing potencies of mAb LAl.
Example 4
[0058] Another in vitro cytotoxicity assay using LAl immunoconjugates was further evaluated using human lung cancer A549 cell line (ATCC No. CCL-185). A549 cells were seeded at 2,000 cells/well of 96-well plate in DMEM-10% FBS. Four hours later, various amounts of LAl, LAl-MMC, or MMC-SPDP were added to the cell cultures. Four days later, the cell numbers in each well were determined by MTT assay. The numbers were expressed as the percentage of the cell death (FIGURE 5). LAl-MMC induced the death of A549 human lung cancer cells in a dose-dependent manner. No significant cell death was observed with mAb LAl alone. Conjugation with mitomycin C significantly increased the cell killing potency of LAl. Example 5
[0059] To test for the effect of LA22-MMC on in vivo tumor toxicity, five week-old female BALB/c mice with a body weight of approximately 20 g were used. Xenografts of
A431 cell lines were produced by injecting 2x106 tumor cells (resuspended in 0.2 rnL PBS) subcutaneously into the right front leg of mice on day 0. The mice were grouped (5 mice per group) and administered intraperitoneally with PBS, MMC, naked antibodies or immunoconjugates with indicated concentrations on day 1, day 5 and day 9. Tumor size was measured three times per week and tumor volume was calculated according to the following equation: tumor size=width2 xlength/2. At the end of the experiment (day 21), the mice were sacrificed and tumors were removed and weighed.
[0060] As illustrated in FIGURE 6A, mice treated with LA22-MMC (0.08 mg/kg) inhibited tumor growth in vivo when compared with control untreated mice. Although MMC (0.08 mg/kg) injection was potent to inhibit tumor growth, the efficiency was much lower than LA22-MMC (0.08 mg/kg), which suggested the great advantage of LA22-mediated specific tumor targeting. Low dosage administration (0.0032 mg/kg) of LA22-MMC was not potent as the high-dosage of LA22-MMC administration (0.08 mg/kg), which suggested the dose-dependent effect of LA22-MMC immunoconjugate. Considering the comparative big errors drawn by measuring tumors, mice were sacrificed and the tumors were weighed (FIGURE 6B). There were no detectable tumors in 2 mice injected with LA22-MMC (0.08 mg/kg). The average tumor size of LA22-MMC (0.08 mg/kg) treatment group was much lower than the other groups. The tumors shrank to 15% comparing with the control group (PBS injected) while the tumors only shrank to 60% after three MMC injections (0.08 mg/kg). These results showed that LA22-MMC was potent to inhibit tumor growth in vivo.
Example 6
[0061] To show the biodistribution of LA22-MMC immunoconjugate, five (5)-week old female BALB/c nude mice, kept under specific pathogen-free condition, were implanted subcutaneously with A431 cells (5x106) or A549 cells (5x106) at their right upper flanks. When the tumors reached ~1.0 cm in mean diameter, the tumor-bearing mice were 'subjected to immunoscintigraphy. To a vial coated with 40 μg Iodogen (Sigma-Aldrich, St. Louis, MO), 100 μg of LA-22-MMC antibody (0.76 mg/niL, in 132 μL) and 100 MBq Of Na125I (Beijing Atom High Tech., Beijing, China) in 0.2M, pH 7.4 phosphate buffer were added. After 10 min of incubation at room temperature, the reaction mixture was purified by a PD- 10 column (Amersham, Piscataway, NJ). Labeling yield and radiochemical purity were measured by ITLC (85% methanol as mobile phase) on a radio-thin layer scanner (Bioscan AR2000, Washington, DC), with more than 85% and 97%, respectively. The nude mice-
bearing A431/A549 xenografts were injected intravenously with 17.6 MBq (~20 μg, 0.3 mL) of 125I-LA22-MMC, and placed prone on a two-head γ-camera (E.CAM, Siemens, Munich, Germany) equipped with a parallel-hole, low-energy, high-resolution collimator. The posterior images were acquired at different time points post-injection for the visual observation of in vivo distribution of LA22-MMC, and stored digitally in a 128 x 128 matrix. The acquisition count limits were set at 1000 K.
[0062] The imaging results from 4h to 7 days are shown on FIGURE 7. 125I labeled
LA22-MMC first distributed in the circulation system and blood-rich tissues such as liver or heart (4h imaging); gradually the labeled immunoconjugates enriched on the tumor sites (1 day to 4 days). After 4 days, LA22-MMC mainly enriched on the tumor sites.
Example 7
[0063] Erbitux® and Herceptin®, two commercially-available mAb drugs for cancer therapy, target EGFR and HER2, respectively. Both EGFR and HER2 belong to the ErbB receptor family (Mendelsohn, J. et ah, Oncogene, 19:6550-7565, 2000). To compare LA22- MMC with Erbitux® and Herceptin®, an in vitro cytotoxicity assay using the MTT method was conducted. The conjugation of MMC with Erbitux® (ImClone, New York, NY) or Herceptin® (Genentech, San Francisco, CA) or mouse IgG was done as described above. [0064] Erbitux® and Herceptin® were labeled with MMC and evaluated for their cytotoxicities. A431 (FIGURE 8A) or A549 (FIGURE 8B) cells were seeded into 96-well cell culture plates. Naked antibodies or immunoconjugates were added to wells and incubated for 4 days at 37°C and 5% CO2. Viable cells were measured using the MTT assay. Using similar antibody concentrations, LA22-MMC prodrug killed A431 and A549 cells more efficiently than Erbitux®-MMC or Herceptin®-MMC (see FIGURES 8A & 8B) . [0065] The foregoing description of the present invention provides illustration and description, but is not intended to be exhaustive or to limit the invention to the precise one disclosed. Modifications and variations are possible consistent with the above teachings or may be acquired from practice of the invention. Thus, it is noted that the scope of the invention is defined by the claims and their equivalents.
Claims
1. An EGFR-binding molecule comprising an antigen-binding fragment of an anti-EGFR monoclonal antibody and a cytotoxic agent, wherein said anti-EGFR monoclonal antibody is selected from the group consisting of LAl and LA22.
2. The EGFR-binding molecule of claim 1, comprising said monoclonal antibody conjugated with said cytotoxic agent.
3. An EGFR-binding molecule according to any one of claims 1 or 2, wherein said cytotoxic agent is a cytotoxic antibiotic.
4. The EGFR-binding molecule of claim 3, wherein said cytotoxic antibiotic is selected from the group consisting of mitomycin C and pingyangmycin.
5. The EGFR-binding molecule of claim 4, wherein said EGFR-binding molecule is an engineered antibody comprising an antigen-binding fragment of LAl or LA22.
6. An EGFR-binding molecule according to any one of claims 1 or 2, wherein said cytotoxic agent is selected from the group consisting of a chemotherapeutic agent, a radioisotope, a cytotoxin, and an anticancer pro-drug activating enzyme.
7. A method for killing or inhibiting the growth of cancer cells, comprising contacting said cells with an EGFR-binding molecule according to any one of claims 1-6.
8. The method of claim 7, wherein said cancer cells are epidermoid cancer cells.
9. The method of claim 7, wherein said cancer cells are lung cancer cells.
10. A method for treating a cancer in a subject of interest, comprising administrating an effective amount of an EGFR-binding molecule according to any one of claims 1-6 to said subject of interest.
11. A pharmaceutical composition comprising an EGFR-binding molecule according to any one of claims 1-6.
12. An anti-EGFR antibody conjugated with mitomycin C or pingyangmycin.
13. The antibody of claim 12, wherein said antibody is a monoclonal antibody.
14. An antibody according to any one of claims 12 or 13, wherein said antibody is an engineered antibody or fragments of antibody.
15. A method for killing or inhibiting the growth of cancer cells, comprising contacting said cells with an antibody according to any one of claims 12-14.
16. A method for treating a cancer in a patient of interest, comprising administrating an effective amount of an antibody according to any one of claims 12-14 to said patient of interest.
17. A pharmaceutical composition comprising an EGFR-binding molecule according to any one of claims 12-14.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06750858A EP1877083A2 (en) | 2005-04-27 | 2006-04-20 | Antibodies for the treatment of cancers |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67509405P | 2005-04-27 | 2005-04-27 | |
US60/675,094 | 2005-04-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006116001A2 true WO2006116001A2 (en) | 2006-11-02 |
WO2006116001A3 WO2006116001A3 (en) | 2006-12-21 |
Family
ID=37215266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/014941 WO2006116001A2 (en) | 2005-04-27 | 2006-04-20 | Antibodies for the treatment of cancers |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1877083A2 (en) |
CN (1) | CN101277716A (en) |
WO (1) | WO2006116001A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7887805B2 (en) | 2007-03-01 | 2011-02-15 | Symphogen A/S | Recombinant anti-epidermal growth factor receptor antibody compositions |
US8663640B2 (en) | 2008-08-29 | 2014-03-04 | Symphogen A/S | Methods using recombinant anti-epidermal growth factor receptor antibody compositions |
CN112176013A (en) * | 2019-07-02 | 2021-01-05 | 华东理工大学 | Method for improving biosynthesis efficiency of pingyangmycin |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104059148B (en) * | 2013-03-18 | 2016-09-07 | 回而生医药科技(北京)有限公司 | humanized anti-human epidermal growth factor receptor antibody and application thereof |
US10611833B2 (en) | 2014-03-07 | 2020-04-07 | Welson Pharmaceuticals, Inc. | Humanized anti-human epidermal growth factor receptor antibody and application thereof |
-
2006
- 2006-04-20 EP EP06750858A patent/EP1877083A2/en not_active Withdrawn
- 2006-04-20 CN CNA2006800186555A patent/CN101277716A/en active Pending
- 2006-04-20 WO PCT/US2006/014941 patent/WO2006116001A2/en active Application Filing
Non-Patent Citations (5)
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7887805B2 (en) | 2007-03-01 | 2011-02-15 | Symphogen A/S | Recombinant anti-epidermal growth factor receptor antibody compositions |
US8414896B2 (en) | 2007-03-01 | 2013-04-09 | Symphogen A/S | Recombinant anti-epidermal growth factor receptor antibody compositions |
US8663640B2 (en) | 2008-08-29 | 2014-03-04 | Symphogen A/S | Methods using recombinant anti-epidermal growth factor receptor antibody compositions |
CN112176013A (en) * | 2019-07-02 | 2021-01-05 | 华东理工大学 | Method for improving biosynthesis efficiency of pingyangmycin |
CN112176013B (en) * | 2019-07-02 | 2022-08-12 | 华东理工大学 | Method for improving biosynthesis efficiency of pingyangmycin |
Also Published As
Publication number | Publication date |
---|---|
CN101277716A (en) | 2008-10-01 |
EP1877083A2 (en) | 2008-01-16 |
WO2006116001A3 (en) | 2006-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8586049B2 (en) | Antibody-drug conjugates | |
US20210024646A1 (en) | Targeted cd73 antibody and antibody-drug conjugate, and preparation method therefor and uses thereof | |
CN111712520A (en) | Glypican 3 antibodies and conjugates thereof | |
US20210017295A1 (en) | Bispecific binding agents and uses thereof | |
WO2017196764A1 (en) | Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses | |
JP2023036874A (en) | Methods of preventing methionine oxidation in immunoconjugates | |
WO2006116001A2 (en) | Antibodies for the treatment of cancers | |
US20100047164A1 (en) | Anti-Tumor Antibodies | |
EP4129335A1 (en) | Anti-c-met antibody-drug conjugate and applications thereof | |
KR20230065935A (en) | therapeutic conjugate | |
JP2020532523A (en) | Anti-EGFR antibody drug conjugate (ADC) and its use | |
Shao et al. | Inhibition of human tumor xenograft growth in nude mice by a conjugate of monoclonal antibody LA22 to epidermal growth factor receptor with anti-tumor antibiotics mitomycin C | |
JP7130243B2 (en) | Antibody-drug conjugate platform using bispecific antibodies | |
JP2020532543A (en) | Anti-EGFR antibody drug conjugate (ADC) and its use | |
WO2023048231A1 (en) | Medicine for killing tumor cells | |
WO2023048233A1 (en) | Medicine for killing tumor cells | |
JP2024519585A (en) | Antibody conjugates containing anti-P-cadherin antibodies and uses thereof | |
CA3070610A1 (en) | Methods and compositions for targeting disease related cell surface receptors using radiolabeled and/or cytotoxin labelled antibodies | |
KR20130138608A (en) | Site-specific antibody-cytotoxin conjugate and use thereof | |
Chauhan et al. | Journal Homepage:-www. journalijar. com | |
NZ615308B2 (en) | Antibody-drug conjugates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680018655.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006750858 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: RU |